title: Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus.
abstract: BACKGROUND
  To evaluate the results of chemoradiotherapy with or without surgery in locally-advanced esophageal carcinomas (T3 and/or nodal involvement).
  
  
  METHODS
  One hundred twelve patients with locally-advanced carcinoma of the esophagus without histologically proven invasion of the tracheobronchial tree or distant visceral metastases were treated with concomitant chemoradiotherapy followed by re-evaluation; surgery was performed or chemoradiotherapy continued, based on tumor regression and the patient's general status. Chemoradiotherapy consisted of concomitant 5-fluorouracil (5FU)(1 g/m(2) day 1-3), cisplatinum (50 mg/m(2) day 1 and 2), and external beam irradiation up to a dose of 40 or 43.2 Gy. After a 4-week rest period, radical esophagectomy or a new cycle of chemoradiotherapy (up to a total dose of 65 Gy) was performed.
  
  
  RESULTS
  A complete clinical response was obtained in 25.7% of the patients and a partial response in 45.9%. Fifty patients underwent surgery, but only 38 patients had an esophagectomy. Post-esophagectomy mortality was 5.3%. A complete histologic response rate of 23.7% was obtained. Two- and 5-year survival rates were, respectively, 41.5% and 28.6% for the whole population. According to multivariate analysis, prognostic factors for survival were Karnofsky index, esophagectomy, and response to chemoradiotherapy. Five-year survival for patients who experienced a partial response to radiation and chemotherapy was 49.1% for those who had surgery and 23.5% for those treated without surgery (p = 0.003). There was no obvious benefit for the small number of patients treated surgically after complete response to radiation and chemotherapy. Toxicity, essentially hematologic, was moderate.
  
  
  CONCLUSIONS
  For locally-advanced esophageal carcinomas, esophagectomy, after concomitant chemoradiotherapy, could improve the survival rate, especially for patients who responded partially to the latter.
authors.affiliation: Service de Cancérologie-Radiotherapie, Hôpital Saint-Louis, 1 avenue Claude vellefeaux, 75010 Paris, France. christophe.hennequin@sls.ap-hop-paris.fr
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.forename: B
authors.initials: B
authors.lastname: Gayet
authors.forename: A
authors.initials: A
authors.lastname: Sauvanet
authors.forename: A
authors.initials: A
authors.lastname: Blazy
authors.forename: T
authors.initials: T
authors.lastname: Perniceni
authors.forename: Y
authors.initials: Y
authors.lastname: Panis
authors.forename: F
authors.initials: F
authors.lastname: Mal
authors.forename: E
authors.initials: E
authors.lastname: Sarfati
authors.forename: P
authors.initials: P
authors.lastname: Valleur
authors.forename: J
authors.initials: J
authors.lastname: Belghiti
authors.forename: F
authors.initials: F
authors.lastname: Fekete
authors.forename: C
authors.initials: C
authors.lastname: Maylin
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery*; D016629:Esophagectomy / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil